155 related articles for article (PubMed ID: 34206581)
1. BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients.
Wischnewsky M; Schwentner L; Diessner JD; De Gregorio A; Joukhadar R; Davut D; Salmen J; Bekes I; Kiesel M; Müller-Reiter M; Blettner M; Wolters R; Janni W; Kreienberg R; Wöckel A; Ebner F
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206581
[TBL] [Abstract][Full Text] [Related]
2. Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.
Ebner F; Salmen J; Dayan D; Kiesel M; Wolters R; Janni W; Wöckel A; Wischnewsky M
Breast Cancer Res Treat; 2023 May; 199(1):173-184. PubMed ID: 36917303
[TBL] [Abstract][Full Text] [Related]
3. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.
Regierer AC; Wolters R; Ufen MP; Weigel A; Novopashenny I; Köhne CH; Samonigg H; Eucker J; Possinger K; Wischnewsky MB
Ann Oncol; 2014 Mar; 25(3):633-638. PubMed ID: 24368402
[TBL] [Abstract][Full Text] [Related]
4. A Prognostic Model for Breast Cancer With Liver Metastasis.
Ji L; Fan L; Zhu X; Gao Y; Wang Z
Front Oncol; 2020; 10():1342. PubMed ID: 33014776
[No Abstract] [Full Text] [Related]
5. Independent Validation of the BRENDA-Score Breast Cancer Prognosis Prediction Tool In Chinese Patients.
Ma S; Liu Y; Gao P; Ma R
Clin Breast Cancer; 2024 Feb; ():. PubMed ID: 38538518
[TBL] [Abstract][Full Text] [Related]
6. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK.
Campbell HE; Gray AM; Harris AL; Briggs AH; Taylor MA
Br J Cancer; 2010 Sep; 103(6):776-86. PubMed ID: 20823886
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Score for
Ji L; Fan L; Zhu X; Gao Y; Wang Z
Front Oncol; 2021; 11():651636. PubMed ID: 34513662
[TBL] [Abstract][Full Text] [Related]
8. Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Leinert E; Schwentner L; Janni W; Wöckel A; Herbert SL; Herr D; Kühn T; Flock F; Felberbaum R; Kreienberg R; Fink V; Dayan D; Ernst K; Singer S;
Breast Cancer; 2022 May; 29(3):429-436. PubMed ID: 35178667
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).
Marschner N; Frank M; Vach W; Ladda E; Karcher A; Winter S; Jänicke M; Trarbach T
Colorectal Dis; 2019 Jul; 21(7):816-826. PubMed ID: 30834622
[TBL] [Abstract][Full Text] [Related]
12. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
14. Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer.
Al jarroudi O; Zaimi A; Brahmi SA; Afqir S
Asian Pac J Cancer Prev; 2019 Jan; 20(1):59-63. PubMed ID: 30678381
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study.
Zheng Y; Wu C; Yan H; Chen S
Clin Chim Acta; 2020 Jul; 506():110-121. PubMed ID: 32156604
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
Elwood JM; Tawfiq E; TinTin S; Marshall RJ; Phung TM; Campbell I; Harvey V; Lawrenson R
BMC Cancer; 2018 Sep; 18(1):897. PubMed ID: 30223800
[TBL] [Abstract][Full Text] [Related]
17. Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Müller HD; Posch F; Suppan C; Bargfrieder U; Gumpoldsberger M; Hammer R; Hauser H; Dandachi N; Prein K; Stoeger H; Lax S; Balic M
Ann Surg Oncol; 2019 Dec; 26(13):4274-4283. PubMed ID: 31452052
[TBL] [Abstract][Full Text] [Related]
18. Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.
Serrero G; Hawkins DM; Bejarano PA; Ioffe O; Tkaczuk KR; Elliott RE; Head JF; Phillips J; Godwin AK; Weaver J; Hicks D; Yue B
Diagn Pathol; 2016 Aug; 11(1):71. PubMed ID: 27501955
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
Akamatsu S; Kubota M; Uozumi R; Narita S; Takahashi M; Mitsuzuka K; Hatakeyama S; Sakurai T; Kawamura S; Ishidoya S; Hoshi S; Ishida M; Mizuno K; Ogura K; Goto T; Terada N; Kobayashi T; Yamasaki T; Inoue T; Tsuchiya N; Ohyama C; Arai Y; Habuchi T; Morita S; Ogawa O
Eur Urol Oncol; 2019 May; 2(3):320-328. PubMed ID: 31200847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
